Imvax has secured $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of its autologous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback